IFNG and cancer: The blocking of PD-L1 can inhibit the glycolysis of cancer cells by inhibiting the activity of mTOR, thereby relieving the pressure of glucose deficiency in the tumor microenvironment and allowing the glycolysis and IFN-γ production of infiltrated T cells [45].